Histology Post-Endoscopic Eradication Therapy (EET)



Status:Completed
Conditions:Gastroesophageal Reflux Disease , Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:12/17/2017
Start Date:August 2, 2017
End Date:November 5, 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Optimizing Patient Outcomes Through Early Detection of Uncontrolled Acid Reflux After Endoscopic Therapy in Barrett's Esophagus

This study is looking at a cohort of patients who have undergone treatment for Barrett's
Esophagus (BE) and who have experienced complete eradication of the disease. The aim of the
proposed study is to evaluate the histologic features of the neosquamous epithelium (NSE)
following complete eradication of intestinal metaplasia (CE-IM) in patients undergoing
routine surveillance biopsies and compare these data to a direct measure of reflux using 24hr
pH impedance, to determine the correlation between histology and persistent reflux. These
data will allow us to more accurately risk stratify patients for recurrence of BE following
EET.


Inclusion Criteria:

- - Patients who have undergone endoscopic eradication therapy and 24hr pH impedance
testing as part of standard of care between 2009 and 2014.

- - Individuals who have signed a consent to be part of the Prospective Evaluation of
Barrett's Esophagus Study population.

Exclusion Criteria:

- - Individuals who are not yet adults (infants, children and teenagers), pregnant women
and prisoners will be excluded from the study.

- - Patient who were previously unable or unwilling to give consent to the Prospective
Evaluation of Barrett's Esophagus Study will be excluded.
We found this trial at
1
site
Northwestern University
303 East Superior Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials